Gold Gains 1%; CXApp Shares Spike Higher

4/1/24 3:02:50 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Clothing/Shoe/Accessory Stores

Consumer Discretionary

Get the next $AEON alert in real time by email

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 0.3% on Monday.

The Dow traded down 0.67% to 39,538.91 while the NASDAQ fell 0.06% to 16,369.44. The S&P 500 also fell, dropping, 0.30% to 5,238.49.

Check This Out: Jim Cramer Likes Crown Castle, But Can't Recommend Archer Aviation: It Has 'No Earnings Power'

Leading and Lagging Sectors

Communication services shares jumped by 1.3% on Monday.

In trading on Monday, real estate shares fell by 1.6%.

Top Headline

Torrid Holdings Inc. (NYSE:CURV) reported better-than-expected fourth-quarter financial results on Thursday.

Equities Trading UP

CXApp Inc. (NASDAQ:CXAI) shares shot up 145% to $6.00 after the company announced a partnership with Google Cloud for acceleration of the CXAI platform.

Shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) got a boost, surging 72% to $0.1039 after the company FY23 operating results.

Doma Holdings Inc. (NYSE:DOMA) shares were also up, gaining 34% to $6.07 after the company entered a merger transaction with TRG to go private at $6.29 per share in cash.

Equities Trading DOWN

Nuvve Holding Corp. (NASDAQ:NVVE) shares dropped 28% to $0.7897 after the company reported worse-than-expected fourth-quarter financial results.

Shares of AEON Biopharma, Inc. (NYSE:AEON) were down 41% to $6.83 after the company reported a fourth-quarter loss of 71 cents per share.

Disc Medicine, Inc. (NASDAQ:IRON) was down, falling 47% to $32.90 after the company reported topline results from the Phase 2 AURORA study of bitopertin in patients with EPP.

Commodities

In commodity news, oil traded up 0.8% to $83.80 while gold traded up 1% at $2,261.30.

Silver traded up 0.8% to $25.12 on Monday, while copper rose 1.1% to $4.0505.

Economics

The ISM manufacturing PMI rose to 50.3 in March versus 47.8 in February and topping market estimates of 48.4.

U.S. construction spending fell by 0.3% from the prior month in February.

The S&P Global manufacturing PMI was revised lower to 51.9 in March compared to a preliminary reading of 52.5.

Now Read This: $5M Bet On Snowflake? Check Out These 4 Stocks Insiders Are Buying

Get the next $AEON alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$AEON
$CURV
$CXAI
$DOMA

Company	Date	Price Target	Rating	Analyst
Disc Medicine Inc. $IRON	11/3/2025	$125.00	Buy	Stifel
Torrid Holdings Inc. $CURV	10/24/2025		Outperform → Mkt Perform	William Blair
Disc Medicine Inc. $IRON	7/21/2025	$86.00	Buy	Truist
Disc Medicine Inc. $IRON	7/3/2025	$85.00	Overweight	Morgan Stanley
Torrid Holdings Inc. $CURV	6/12/2025		Neutral	BTIG Research
Disc Medicine Inc. $IRON	6/11/2025	$89.00	Strong Buy	Raymond James
Torrid Holdings Inc. $CURV	4/22/2025	$4.00	Neutral → Sell	Goldman
Torrid Holdings Inc. $CURV	3/21/2025	$5.00 → $6.00	Market Perform	Telsey Advisory Group

More analyst ratings

$AEON
$CURV
$CXAI
$DOMA
Financials

Live finance-specific insights

Torrid Reports Third Quarter 2025 Results

Delivered Third Quarter Net Sales in line with guidance Third Quarter Net Loss of $6.4 million Updates Fiscal 2025 Guidance Torrid Holdings Inc. ("Torrid" or the "Company") (NYSE:CURV), a direct-to-consumer apparel, intimates, and accessories brand in North America for women sizes 10 to 30, today announced its financial results for the quarter ended November 1, 2025. "Our third quarter results fell short of our expectations due to execution missteps that were largely within our control. While several core categories delivered strong comparable growth, these gains were more than offset by an imbalance in our assortment mix. We have already taken decisive corrective actions and are se

12/3/25 4:05:00 PM ET

Clothing/Shoe/Accessory Stores

Consumer Discretionary

Torrid Announces Reporting Date for Third Quarter Fiscal 2025 Financial Results

Torrid Holdings Inc. ("Torrid" or the "Company") (NYSE:CURV), a direct-to-consumer apparel, intimates, and accessories brand in North America for women sizes 10 to 30, today announced that it will release its third quarter fiscal 2025 financial results after market close on Wednesday, December 3, 2025. Management will host a conference call that afternoon at 4:30 p.m. Eastern Time to discuss its financial results. Those who wish to participate in the call may do so by dialing (877) 407-9208 or (201) 493-6784 for international callers. The conference call will also be webcast live at https://investors.torrid.com. For those unable to participate, a replay of the conference call will be av

11/19/25 4:05:00 PM ET

Clothing/Shoe/Accessory Stores

Consumer Discretionary

AEON Biopharma Reports Third Quarter 2025 Results, Including Positive ABP-450 Biosimilarity Data and Strategic Positioning for Continued Growth

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON's balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE

11/14/25 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

$AEON
$CURV
$CXAI
$DOMA
Leadership Updates

Live Leadership Updates

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Lisa Amaya Price, MBA as the company's Chief Human Resources (HR) Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including at multiple commercial-stage companies. "As we move towards commercialization, we have meaningfully increased hiring to support these efforts and Lisa will play a central role in building a strong, scal

1/12/26 4:30:00 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

DeFi Technologies to Manage Nuvve's HYPE Treasury Strategy Through Newly Launched DeFi Advisory Business Line

DeFi Technologies has launched its DeFi Advisory business line to provide institutional-grade digital asset treasury solutions for public companies, offering asset management, trade execution, and strategic advisory through an integrated platform. The Advisory division's first mandate is with Nuvve Holding Corp., which has appointed DeFi Technologies to manage its HYPE token treasury strategy, including custody, OTC execution via Stillman Digital, and performance optimization.DeFi Technologies will earn recurring management fees based on treasury AUM, paid quarterly in either equity or cash, reinforcing the Company's scalable, fee-based business model as public market participation in digita

7/21/25 7:30:00 AM ET

Finance: Consumer Services

Finance

Electrical Products

Industrials

Disc Medicine Appoints Nadim Ahmed to its Board of Directors

WATERTOWN, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the appointment of Nadim Ahmed to its Board of Directors. Mr. Ahmed is currently the President and Chief Executive Officer of Cullinan Therapeutics. "I am excited to welcome Nadim to Disc's Board of Directors at such a pivotal moment for the company," said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. "His track record of successful drug launches and deep expertise in hematological

7/14/25 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care